Extension Study to Evaluate the Long-Term Outcomes of Pediatric Patients Who Received Treatment for Retinopathy of Prematurity in the VGFTe-ROP-1920 Study (Acronym: Butterfleye Next)
Active, not recruiting · NCT04515524
Conditions: Retinopathy of Prematurity
At a glance
- Research payments reported, 2025
- $26,206
- U.S. investigators named
- 7
- Sites paid
- 7
- Planned or actual enrollment
- 100
About the trial
- Sponsor
- Regeneron Pharmaceuticals
- Tested
- Non-Interventional (other)
- Dates
- Started 2021-02-05; completion 2026-11-05
- Results posted
- Not yet
Primary objectives of the study are: * To evaluate binocular visual acuity at the end of this study in patients included from the VGFTe-ROP-1920 study, for treatment of Retinopathy of Prematurity (ROP). * To evaluate long-term safety outcomes in patients included from the VGFTe-ROP-1920 study, for treatment of ROP. Secondary objectives of the study are: * To describe visual function in patients included from the VGFTe-ROP-1920 study, for treatment of ROP. * To describe overall development in patients included from the VGFTe-ROP-1920 study, for treatment of ROP.
From ClinicalTrials.gov, last updated 2026-03-27. Full record, eligibility and contacts (opens in a new tab)
Industry funding
Regeneron Pharmaceuticals, Inc. reported $26,206 in research payments for this study in 2025 (23 payments).
Products named: Eylea
Research payments usually go to hospitals, universities and research sites to run a study, not to the investigators personally. A payment is not evidence of wrongdoing.
U.S. investigators named on this study
- Alejandra G. De Alba Campomanes, MD, MPH Ophthalmology · San Francisco, CA
- Jennifer A. Dunbar, M.D. Ophthalmology · San Bernardino, CA
- Eric D. Nudleman, M.D., PH.D. Ophthalmology · San Diego, CA
- Vaidehi S. Dedania, M.D. Ophthalmology · New York, NY
- Robin Ginsburg, M.D. Ophthalmology · New York, NY
- Maryo C. Kohen Ophthalmology · Cleveland, OH
- Martin Keszler, M.D. Neonatology · Providence, RI
Clinicians the company named as principal investigators in its Open Payments reports.
Sites paid to run it
- UCSF Langley Porter Psychiatric Hospital and Clinics, CA $8,206
- New York University $6,625
- Rainbow Babies and Childrens Hospital, OH $5,000
- Icahn School of Medicine at Mount Sinai $2,105
- Women & Infants Hospital of Rhode Island, RI $1,702
- Resnick Neuropsychiatric Hospital at UCLA, CA $1,300
- Loma Linda University Health $1,268
Sources: CMS Open Payments research payments (program year 2025) and ClinicalTrials.gov, U.S. National Library of Medicine.